Which of the following statements best describes the mechanism of action of insulin on target cells?

Insulin binds to a transmembrane receptor on the outer surface of the plasma membrane, activating the tyrosine kinase in the cytosolic domain of the receptor.

Insulin binds to a receptor on the outer surface of the plasma membrane, activating adenylate cyclase through the Gs protein.

Insulin binds to a cytoplasmic receptor and is transferred as a hormone receptor complex to the nucleus to modulate gene expression.

Insulin enters the cell and causes the release of calcium ions from intracellular stores.

What is the primary mechanism of action of opioids in pain management?

Activation of opioid receptors at both spinal and supraspinal levels

Inhibition of cyclooxygenase (COX) enzymes

Activation of opioid receptors in the spinal cord only

Activation of opioid receptors in the brain only

A research team is developing a gene therapy approach using CRISPR-Cas9 to correct a point mutation causing sickle cell disease. They must decide between two strategies: (A) correcting the mutation in hematopoietic stem cells ex vivo, or (B) in vivo correction in bone marrow. Considering molecular physiology principles, what is the most significant advantage of strategy A over strategy B?

Strategy A allows for screening and selection of successfully edited cells before transplantation, minimizing off-target effects

Strategy A requires lower doses of viral vectors

Strategy A produces faster clinical improvement

Strategy A is less expensive to implement

A novel drug is designed to treat a genetic disorder caused by a nonsense mutation in the dystrophin gene. The drug works by allowing the ribosome to skip over the premature stop codon and continue translation. Evaluation of this therapeutic strategy reveals partial restoration of dystrophin protein with 60% of normal length but sufficient function. What is the most critical molecular consideration in determining if this approach will be clinically beneficial?

Whether the truncated protein retains the actin-binding domain and maintains membrane stability

Whether the drug prevents degradation of dystrophin mRNA

Whether the drug enhances ribosomal binding to the start codon

Whether the drug increases transcription of the dystrophin gene

Receptor-Ligand Interactions for INI-CET: High-Yield Physiology Lessons

Receptor-Ligand Interactions: Basics - Keys & Locks

Receptor: Cellular macromolecule (protein/glycoprotein) that binds specific signaling molecules (ligands).
- Locations: Cell membrane, cytoplasm, nucleus.
Ligand: Molecule that binds to a receptor (e.g., hormone, neurotransmitter, drug).
- Endogenous: Produced by the body.
- Exogenous: Originates outside the body (e.g., drugs).
Interaction Specificity: "Lock & Key" model (rigid fit) or "Induced Fit" model (flexible, conformational change).
Affinity: Strength of binding between ligand and receptor. High affinity = strong attraction.
Intrinsic Activity (Efficacy): Ability of a ligand-receptor complex to produce a functional response.
Agonist: Binds receptor, activates it, produces a response (has efficacy).
Antagonist: Binds receptor, no activation, blocks agonist action (no efficacy).

⭐ Most therapeutic drugs exert their effects by interacting with specific receptors, acting as agonists or antagonists.

Receptor-Ligand Interactions: Kinetics - The Dating Game

Affinity: Strength of ligand-receptor bond.
- $K_d$ (dissociation constant): Ligand concentration for 50% receptor occupancy. $K_d = [R][L]/[RL]$.
- ↓$K_d$ = ↑Affinity (tight binding).
- ↑$K_d$ = ↓Affinity (loose binding).
⭐ $K_d$ (dissociation constant) is inversely proportional to binding affinity; a lower $K_d$ indicates higher affinity and tighter binding.
Specificity: Receptor's ability to bind specific ligands.
Saturation: Finite receptors; max effect when all bound.
Scatchard Plot: Analyzes $K_d$ & $B_{max}$ (total receptors).
- Slope = $-1/K_d$. X-intercept = $B_{max}$.
Dose-Response Curves:
- Potency: Drug conc. for 50% max effect ($EC_{50}$). Left shift = ↑Potency.
- Efficacy: Max possible effect ($E_{max}$).
Antagonism:
- Competitive: Reversible; agonist site. ↓Potency, $E_{max}$ same. Overcome by ↑agonist.
- Non-competitive: Allosteric/irreversible. ↓$E_{max}$ (efficacy).

Receptor-Ligand Interactions: Types - Cellular Switchboards

Receptors act as cellular switchboards, translating extracellular signals into intracellular responses. Major types differ in structure, location, and mechanism:

Major cell receptor types and signaling pathways

Receptor Superfamily	Location	Coupling	Effector Pathway	Speed	Examples
Ligand-Gated Ion Channels (Ionotropic)	Cell Membrane	Direct	Ion flux ($Na^+$, $K^+$, $Ca^{2+}$, $Cl^-$)	Very Fast (ms)	Nicotinic AChR, GABA-A, Glutamate (NMDA, AMPA)
G-Protein Coupled Receptors (GPCRs)	Cell Membrane	G-Protein	2nd messengers ($cAMP$, $IP_3$/$DAG$, $Ca^{2+}$)	Fast (s-min)	Adrenergic, Muscarinic AChR, Opioid, Glucagon
Enzyme-Linked Receptors	Cell Membrane	Direct/Associated	Enzyme activity (Tyr Kinase, Ser/Thr Kinase, Guanylyl Cyclase)	Slow (min-hr)	Insulin, Growth Factors (EGF, PDGF), ANP
Nuclear Receptors (Intracellular)	Cytosol/Nucleus	Direct	Gene transcription modulation	Very Slow (hr-days)	Steroids, Thyroid Hormones, Vit D, Retinoids

-   Gs: Stimulates adenylyl cyclase → ↑$cAMP$.
-   Gi: Inhibits adenylyl cyclase → ↓$cAMP$; opens $K^+$ channels.
-   Gq: Activates phospholipase C → ↑$IP_3$ & $DAG$ → ↑$Ca^{2+}$ & PKC activation.

⭐ G-Protein Coupled Receptors (GPCRs) constitute the largest family of cell surface receptors and are targets for approximately 30-40% of all modern medicinal drugs.

Receptor-Ligand Interactions: Regulation - Cellular Mood Swings

Receptors dynamic: number & sensitivity modulate.
Upregulation: ↑ receptor number/sensitivity (e.g., prolonged antagonist).
Downregulation: ↓ receptor number/sensitivity (e.g., prolonged agonist); internalization.
Desensitization: ↓ receptor responsiveness (e.g., phosphorylation).
Tolerance: Gradual ↓ drug effect with chronic use.

⭐ Tachyphylaxis refers to the rapid decrease in response to a drug after repeated doses over a short period, often due to receptor desensitization or depletion of mediators.

High‑Yield Points - ⚡ Biggest Takeaways

Affinity (Kd): Strength of ligand-receptor binding; low Kd = high affinity.

Specificity: Receptors bind specific ligands, ensuring precise cellular responses.

Saturation: Finite receptor numbers limit the maximal effect of a ligand.

Agonists (full, partial, inverse) activate receptors; antagonists (competitive, non-competitive) block them.

Competitive antagonists increase ED50; non-competitive antagonists decrease Emax.

Spare receptors enable maximal response without 100% receptor occupancy.

Receptor downregulation/desensitization occurs with prolonged agonist exposure.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play